REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Science & Research
14

Scientific Literature Review: Compounded Semaglutide

Lane Baker·25 days ago
Compiling a literature review on Compounded Semaglutide for community reference. I have gone through PubMed and pulled the most relevant publications. Total published studies referencing Compounded Semaglutide: dozens, ranging from basic science to clinical trials. The quality varies considerably, with some well-designed RCTs and many smaller observational studies and case reports. Mechanism studies: the receptor pharmacology of Compounded Semaglutide is well-characterized. Multiple groups have independently confirmed the binding profile and downstream signaling pathways. This is actually a strength of the evidence base — independent replication increases confidence. Efficacy studies: the clinical trial data shows consistent moderate effects on primary endpoints related to recovery, tissue repair, and relevant biomarkers. Effect sizes in the range of 15-30 percent improvement over placebo are typical, which is clinically meaningful. Safety studies: Compounded Semaglutide has a clean safety record in published literature. The incidence of adverse events is low and severity is mild. No dose-limiting toxicities have been identified within the studied dose ranges. Gaps in the literature: we need more long-duration studies, more diverse study populations, and more head-to-head comparisons with alternative approaches. The existing data is encouraging but incomplete. I maintain a running list of key papers and will share it in the comments for anyone who wants to do their own reading.

Comments (5)

Gem BishopDEMO·25 days ago

I ran Compounded Semaglutide at a slightly higher dose than what you used and found the results were actually about the same. This lines up with the dose-response data suggesting there is a ceiling effect. Higher dose just meant more injection site irritation without additional benefit. Your approach seems well-calibrated.

7
Jules HessDEMO·24 days ago

The sleep improvement you mention with Compounded Semaglutide has been the most universally reported benefit I see across different users. It seems like regardless of primary goals, almost everyone reports better sleep quality. I wonder if this is a direct effect or downstream from other physiological changes.

2
Heath GriffinDEMO·24 days ago

Thanks for the detailed protocol breakdown. I am starting Compounded Semaglutide next week and this is exactly the kind of practical information I was looking for. The reconstitution tips especially — I have seen conflicting advice elsewhere about water temperature and injection speed. Your approach sounds well-reasoned.

3
Ash ArcherDEMO·24 days ago

Been following this thread with interest. My Compounded Semaglutide experience was similar in most ways, though I found the recovery benefits took a bit longer to kick in for me — closer to week 5-6 rather than 3-4. Individual variation is real and I think people need to be patient before concluding something is or is not working.

4
Rue JarvisDEMO·24 days ago

Solid protocol. One suggestion: consider adding HRV tracking if you are not already. It has been the most objective and responsive metric for me during my Compounded Semaglutide protocol. Changes in HRV preceded subjective improvements by about a week, which gave me early confidence the protocol was working.

5

Sign in to comment.